

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3974040
<b>Application Number:</b>	10657363
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3135
<b>Title of Invention:</b>	Ultra high affinity neutralizing antibodies
<b>First Named Inventor/Applicant Name:</b>	James F. Young
<b>Customer Number:</b>	20583
<b>Filer:</b>	Tamera Weisser/Eric Bacig
<b>Filer Authorized By:</b>	Tamera Weisser
<b>Attorney Docket Number:</b>	10271-159-999
<b>Receipt Date:</b>	22-SEP-2008
<b>Filing Date:</b>	08-SEP-2003
<b>Time Stamp:</b>	20:02:44
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	GLEZEN_J_Pediatr_708.pdf	663365 5d8b467c6c14d8b38aa14d3154790139536d1	no	8

### Warnings:

### Information:

2	NPL Documents	GROOTHUIS_Pediatrics_199.pdf	574388 41d89eb922546c05d8d397c23ebac02510071	no	5
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	GROOTHUIS_N_Engl_J_Med_1524.pdf	936112 38bab15a025eebca2ab4a1e7b7c7d901411049db	no	7
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	HACKING_J_Infection_18.pdf	694344 efc36d3184802880-01-00051b764a8b037e53	no	7
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	HALL_N_Engl_J_Med_1343.pdf	474755 6a1588dec118ed3d796d9ee56ab07ac9ab0	no	5
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	HALL_N_Engl_J_Med_393.pdf	437799 12173b99647959e79eaf135e918d6f57bd3af	no	4
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	HALL_N_Engl_J_Med_1443.pdf	587626 6806cfe925ba7996d1f6eb0f6ee97ba226adfd	no	6
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	HALL_JAMA_3047.pdf	639680 ad15d576caterfb234de8226d23c54f5288bda	no	6
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	HALL_Pedi_Inf_Dis_1653.pdf	5635069 7b7427d296e5d8ee051b0bbe95613ee51b79bda	no	26
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	HALL_Pediatrics_92.pdf	2283133 a19c29295439ae424f6613dd8ee299f9d6948da	no	14
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	HALL_Princ_Pract_Infect_Dis_1501.pdf	2637040 /c912/fb1a1a3cf8f875176ad9940f0d70086	no	21
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	HEARD_Mol_Med_35.pdf	1254532 10ba1c5e67dcb4b79f906a3ba956a9b7c8f15	no	11
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	HEFTA_Immunotech_49.pdf	955568 8bc41f63e2c3ef561628879b18228ee88101a	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	HEMMINGJ_Infect_Dis_1083.pdf	441225 a3c7b84629ebc1falc7e41788ba7265d7126	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	HEMMING_Clin_Use_of_IntraJmmunogl_285.pdf	1148864 68ec47ee0428d186d3c3c8e36a76c7e65d6f	no	12
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	HENDERSON_N_Engl_J_Med_S30.pdf	522014 106d8b154024114056ca7dc05eb94499054c5	no	5
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	HERTZ_Medicine_269.pdf	1263465 30941e87a2d4e1061ab0f7078b08c27b5a7060	no	13
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	KIM_Am_J_Epidemiol_422.pdf	1432264 4905a015c0b65ac98009a21a7c7e6d0c6b368	no	13
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	KUNKEL_Meth_Enzymol_367.pdf	1583006 8c118a4d371cedf9f8788f2c6d4d32d97a976f9c	no	16
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	LAM_Prop_Int_Symp_Cont_Rel _Bioact_Mat_759.pdf	160226 <small>5b56c9a69661a7d979ba033e382855e2ef 6e35</small>	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			24324475		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					